Mazdutide 10mg we yu de yuz

▎ Mazdutide Struktrɔ

Sos: PubChem

Sikyɔn: AEGTFTSDVSSYLEGQAAKFIAWLVKGRG Mɔlikul Fɔmula: C 207H 317N 45O65 Molekyula Weyt: 4476g/mol CAS Nɔmba: 2259884-03-0 PubChem CID: 167312357, ɛn di ɔda wan dɛn Sinonim dɛn: GLXC-26803

▎ Mazdutide Risach

Wetin na di risach bakgrɔn fɔ Mazdutide?

Di impɔtant tin bɔt di wɔl fat ɛn sik dɛn we gɛt fɔ du wit am: 

Ovaweit ɛn fat dɔn bi big big prɔblɛm dɛn we de ambɔg pipul dɛn wɛlbɔdi na di wɔl mɔ ɛn mɔ. Di World Obesity Atlas bin tɔk se di nɔmba fɔ pipul dɛn we fat ɔlsay na di wɔl bin rich 764 milyɔn insay 2020 ɛn dɛn tink se i go go ɔp to 1 bilyɔn bay 2030. If pɔsin fat kin mek bɔku prɔblɛm dɛn we kin apin to pɔsin in wɛlbɔdi biznɛs, lɛk sik dɛn we de mek pɔsin in at ɛn di blɔd ɛn tayp 2 dayabitis, we kin rili afɛkt di pɔsin in kwaliti fɔ liv ɛn di mɛrɛsin we i gɛt na di wɔl. Dis dɔn mek di wan dɛn we de stɔdi bɔt dis dɔn tray fɔ no aw fɔ trit pɔsin fayn, mɔ di nyu mɛrɛsin dɛn.

di divεlכpmεnt fawndeshכn fכ inkrεtin-bεys drog dεm: 

Frɔm we dɛn bin de tɔk bɔt inkrɛtin insay 1932, di risach we gɛt fɔ du wit dis dɔn de go bifo ɔltɛm. insay 1987, dεn bin no se GLP-1 na di kכl rεgεlεt fכ insulin sekreshכn na di pankrεas, εn dεn bin divεlכp tritmεnt rεjim fכ tayp 2 dayabεtis we bεys pan inkrεtin. Insay 2005, dɛn bin apruv exenatide, di fɔs GLP-1 riseptɔ agonist (GLP-1RA) na di wɔl fɔ makɛt, we lay wan sɔlid tiori ɛn prɛktikal fawndeshɔn fɔ di risach ɛn divɛlɔpmɛnt fɔ nyu inkrɛtin-bɛs drɔgs lɛk Mazdutide. Mazdutide na wan analכg fכ mamalian oxyntomodulin (OXM). as nyu jεnereshכn dual agonist we de tכk bכt GLP-1R εn GCGR, i gεt wan yכnik dual-akshכn mεkanism εn brayt prכspεkt fכ di tritmεnt fכ weit lכs εn sik dεm we de rilet to am.

Wetin na di mɛkanism fɔ akshɔn fɔ Mazdutide?

Agonistic ifekt pan di glukagon-layk pεptida-1 (GLP-1) rεsεptכr: 

GLP-1 na intestinal כmon we kin mek insulin sekreshכn εn inhibit glukagon sekreshכn insay wan we we dipεnd pan glukכs kכnsantreshכn, we de ridyus di glukכs lεvεl na di bכdi ^[1] . as GLP-1 risεptor agonist, Mazdutide de miks di akshכn fכ GLP-1, we de εnhans insulin sekreshכn εn ridyus glukagon rilis, we de εp fכ rεgεl di blכd glukכs. pan tap dat, di GLP-1 rεsεpכta agonist dεm kin delay di gεstrik εmpti, εnhans di satiety, εn rεdכks fכ it, we bεnεfit fכ kכntrכl di wet ^{[1, 2].}.

Agonistic ifekt pan di glukagon rεsεptכr: 

Glucagon kin mek di liva glycogen brok dכn εn gluconeogenesis, we kin mek di glukoz na di bכdi go כp. Mazdutide, bay we i de aktibכt di glukagon rεsεpכta, kin rεgεl mכltipכl aspek dεm fכ glukכs mεtabolism, we de achy fayn rεgulεshכn fכ di glukכs na di bכdi. Glucagon de mek bak lipolysis, i de ɛp fɔ ridyus di fat we de gɛda ɛn fɔ mek di bɔdi wet smɔl ^{[1, 2].}.

Rigyuletɔri ifɛkt pan blɔd prɛshɔn: 

Mazdutide kin ridyus ɔl tu di sistolik ɛn diastolik blɔd prɛshɔn. na wan say, i de lכs bכdi prεshכn bay we i de rεgεl di glukכs εn lipid mεtabolism εn i de impruv di vaskulεr εndoteyl fכnshכn; na di כda say, i kin afekt di bכdi prεshכn rεguleshכn mεkanism dεm lεk di renin-angiotensin sistεm.

Wetin na di patikyula mɛkanism fɔ Mazdutide fɔ lɔs wet?

rεgulεshכn fכ di glukכs na di bכdi εn mεtabolism: 

as dual agonist fכ di glukagon lεk pεptida-1 (GLP-1) εn glukagon rεsεpכta dεm, wan pan di mכltipכl fysiolojikal ifekt dεm fכ GLP-1 na fכ rεgεl di blכd glukכs lεvεl. I de mek insulin kɔmɔt, i de mek di glukagon nɔ kɔmɔt fayn, i de mek di glukɔs we de na di blɔd nɔ bɔku ^[1] , i de mek di bɛlɛ nɔ ɛmti, i de mek pɔsin satisfay, ɛn i de mek di it nɔ bɔku. di כda say, glukagon de mek di lipolysis εn di εnεji kכnsכm. fכ dat, Mazdutide de aktibכt כl tu di rεsεpכta dεm εn de rεgεl di bכdi glukכs mεtabolism fכ achyv di wet lכs. Stɔdi dɔn sho se Mazdutide kin ridyus di bɔdi wet, blɔd prɛshɔn (systolic ɛn diastolic), tɔtal kɔlɔstrel, triglisɛrɛyd, low-density lipoprotein, ɛn high-density lipoprotein lɛvɛl ^[3] , we sho se i kin mek pɔsin lɔs in wet ɛn impruv di mɛtabolik dizayd we gɛt fɔ du wit fat.

Influɛns pan di apɛtit ɛn di ɛnaji we pɔsin de it: 

Mazdutide kin ajɔst di wet lɔs bay we i de inflɔws di apɛtit ɛn di ɛnaji we i de tek. insay sɔm klinik trial, di patisipan dεm bin εkspiriεns gεstrointestinal riakshכn lεk di dεkrεshכn fכ it afta dεn yuz Mazdutide ^[3] . dis kin bi fכ di dayrekt akshכn we Mazdutide de du pan di gεstrointestinal trakt כ tru rεguleshכn we di sεntri nεv sεstem de du. I nɔ mata di we aw dɛn de du am, we pɔsin nɔ want fɔ it ɛn di sayd ɛfɛkt dɛn we de na di bɛlɛ go mek i nɔ gɛt bɔku ɛnaji ɛn i go mek i nɔ gɛt bɔku bɔku bɔdi. apat frכm dat, Mazdutide kin afekt di apεtit bay we i de rεgεl di nyurotransmit dεm εn di כmon dεm na di bren. fכ egzampl, GLP-1 kin akt pan di haypothalamus fכ rεgεl di apεtit εn εnεji bεlε ^[4]..

Wetin na di spεsifi k akshכn path dεm fכ Mazdutide fכ rεgεl di bכdi glukכs?

Stimulation of insulin sekreshכn: 

glukagon lεk pεptida-1 (GLP-1) rεsεpכta agonist dεm kin mek insulin sekreshכn. as dual agonist fכ GLP-1 εn glukagon rεsεpכta dεm, Mazdutide kin aktibכt di GLP-1 rεsεpכta fכ promp pankrεas aylet β sεl dεm fכ sekret insulin. Insulin na wan impɔtant ɔmon fɔ ridyus di glukɔs na di blɔd, we kin mek di sɛl dɛn tek glukɔs ɛn mek di glukɔs na di blɔd go dɔŋ ^[1]..

Inhibishכn fכ glukagon sekreshכn: 

di sem tεm, Mazdutide kin akt pan di glukagon rεsεpכta fכ inhibit glukagon sekreshכn. Glucagon ɛn insulin de agens dɛnsɛf fɔ rigul di glukɔs na di blɔd, ɛn fɔ ridyus di sekreshɔn we i de mek i fayn fɔ mek di glukɔs na di blɔd go dɔŋ ^[1]..

Rεgulεshכn fכ glukכs mεtabolism: 

mazdutide kin rεgεl di glukכs mεtabolism pan mכltipכl lεvεl dεm fכ εksεrt in haypoglycemic ifekt, lεk fכ afekt di glukכs mεtabolism na di liva, mכsul, εn adipos tisu dεm. insay di liva, i de ridyus di brok dכwn fכ di liva glycogen εn gluconeogenesis, we de dכn di prodakshכn fכ di bכdi glukכs; insay di mכsul tisu, i de protεkt di כptek εn yutilizeshכn fכ glukכs; insay adipos tisu, i de rεgεl di lipid mεtabolism, i de ridyus di rilis fכ fri fεt asid dεm, εn i de afekt di bכdi glukכs indaykt wan ^{[1, 3].}.

Influɛns pan di apɛtit ɛn di ɛnaji we pɔsin de it: 

stכdi dεn dכn fכnshכn se Mazdutide kin ridyus di apεtit εn εnεji intayk, i kin bi bay we i de akt pan rεsεpכta dεm na di sεntri nεv sεstem εn rεgεl di apεtit signal path. if yu ridyus di it we yu de it, i kin mek di blɔd glukɔs kɔmɔt ɛn i kin ɛp fɔ kɔntrol di glukɔs we de na di blɔd ^{[3, 5].}.

chenj frכm di beslayn insay di bכdi wet εn di wεst sεkכnfεnshכn.

a.Pεsεnt chenj frכm di bεslayn in bכdi wet ova tεm. b. Chenj frכm beslayn in bכdi wet ova tεm.

Sos:PubMed ^{[2] we dɛn pul am.}

Wetin na di aplikeshɔn dɛn fɔ Mazdutide?

Tritmɛnt fɔ tayp 2 dayabitis: 

Wan randomized, double-blind, placebo-controlled Phase 2 trial sho se Mazdutide, we na dual agonist we dɛn kin gi ɛvri wik fɔ glukagon-layk peptide 1 (GLP-1) ɛn glucagon riseptɔ, sho gud ɛfifikɛshɔn ɛn sef pan Chaynish pasɛnt dɛn we gɛt tayp 2 dayabitis ^[1]..

Aplikeshɔn fɔ lɔs wet: 

Risach pan pipul dɛm wae gɛt ɛn nɔr gɛt dayabitis: Wan sistamat rivyu ɛn mɛta-analysis sho se Mazdutide kin ridyus di bɔdi wet fɔ big pipul dɛm wae gɛt ɔr nɔr gɛt dayabitis ^[3] . Di risach inklud sɛvin randomized kɔntrol trial wit wan totɛl 680 patisipan dɛn. Di risal sho se we yu kɔmpia am wit di plasɛbo, Mazdutide lid to wan mɔ signifyant ridyushɔn pan bɔdi wet (min difrɛns [MD] = -6.22%, 95% kɔnfidɛns intaval [CI]: -8.02% to -4.41%, I⊃2; = 90.0%) (Nalisa DL, 2024). Sabgrup ɛn mɛta-rɛgrɛshɔn analisis sho se di wan dɛn we nɔ gɛt dayabitis bin gɛt mɔ signifyant weit lɔs, ɛn di wan dɛn we dɛn trit fɔ 24 wik bin gɛt mɔ prominɛnt weit ridɔkshɔn kɔmpia to di wan dɛn we dɛn trit fɔ 12 - 20 wik ^[3]..

Aplikeshɔn fɔ Chaynish big pipul dɛn we gɛt bɔku bɔku bɔdi ɔ we fat pasmak: 

Wan mid-tɛm analisis fɔ wan randomized, tu-pat (lɔ doz te to 6mg ɛn ay doz 9mg), dabl-blaynd, plasɛbo-kɔntrol Faz 2 trayal we dɛn du pan Chaynish big pipul dɛn we gɛt ɔvaweit ɔ fat sho se Mazdutide bin sef ɛn ifektiv insay dis pipul dɛn insay di 24 wik tritmɛnt tɛm, we briŋ kam signifyant ɛn klinikli mininful weit lɔs ^[2] . Insay di stɔdi, dɛn bin asaynd big pipul dɛn we gɛt ɔvawej (BMI ≥ 24 kg/m²) we gɛt haypafagia ɛn/ɔ at le wan kɔmɔrɔbiditi we gɛt fɔ du wit fat, ɔ big pipul dɛn we fat (BMI ≥ 28 kg/m²) fɔ gɛt Mazdutide ɛvri wik pan dos dɛn we na 3mg, 4.5mg, 6mg ɔ a we de mach wit plasɛbo. Di risal sho se frɔm di beslayn to di 24 wik, di min pasɛnt chenj na di bɔdi wet na bin -6.7% (standad mistek 0.7) na di 3mg Mazdutide grup, -10.4% (0.7) na di 4.5mg grup, -11.3% (0.7) na di 6mg grup, ɛn 1.0% (0.7) na di plesbo grup. We yu kɔmpia am wit di plesibo, di tritmɛnt difrɛns bin de frɔm -7.7% to -12.3% (ɔl p < 0.0001) ^[2]..

Fɔ dɔn, as inovativ dual-target agonist, tru bɔku bɔku mɛkanism dɛm lɛk fɔ rigul di blɔd glukɔs, fɔ mek di fat mɛtabolism, ɛn fɔ mek dɛn nɔ want fɔ it, Mazdutide kin rili ɛp fɔ mek di blɔd glukɔs lɛvɛl fɔ di wan dɛn we gɛt tayp 2 dayabitis bɛtɛ ɛn ɛp pipul dɛn we fat fɔ lɔs dɛn wet. I de injekt nyu vitality insay di tritmɛnt fɔ mɛtabolik sik dɛm ɛn dɛn de ɛkspɛkt fɔ mek di glob ɔl lod fɔ fat ɛn sik dɛm we gɛt fɔ du wit am nɔ bɔku.

Bɔt di pɔsin we rayt di buk

Di tin dɛm we wi dɔn tɔk bɔt ɔp na ɔl di risach, ɛdit ɛn kɔmpilayt na Cocer Peptides.

Sayɛns Jɔnal Author

Zhang B na wan ayli - kwalifay masta sabi bukman we gɛt fɔ du wit bɔku ɔganayzeshɔn dɛn we gɛt nem. Dɛn wan ya na Pekin Yuniɔn Mɛdikal Kɔlej, Chaynish Akademi fɔ Mɛdikal Sayns -Pekin Yuniɔn Mɛdikal Kɔlej, - Japan Friendship Ospital, Guizhou Ikwipmɛnt Mfg Politek, Shanghai Jiao Tong Yunivasiti, Yunivasiti Utara Malezya, Yingkou Instityut fɔ Tɛknɔlɔji, Zhejiang Yunivasiti, ɛn Peking Yuniɔn Mɛdikal Kɔlej Ospital. Dɛn kayn difrɛn institiushɔnal kɔnekshɔn ya de sho in brayt akademik ɛn risach bakgrɔn.

We i kam pan risach, Zhang B gɛt bɔku bɔku sɔbjɛkt kategori dɛn. In ɛkspɛriɛns kɔba Ɛndokrinɔlɔji & Mɛtabolism, Jɛnɛral & Intanɛt Mɛdisin, Ɔnkɔlɔji, Kadiɔvaskyuɛl Sistɛm & Kadiɔlɔji, ɛn Rediolɔji, Nyuklia Mɛdisin & Mɛdikal Imej. Di wok we i de du pan dɛn tin ya de sho se i gɛt dip no ɛn i dɔn ɛp fɔ mek di mɛdikal sayɛns go bifo ɛn fɔ mek di we aw dɛn de kia fɔ wɛlbɔdi biznɛs bɛtɛ. Zhang B de na di list insay di rɛfrɛns fɔ saytayshɔn [1].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Zhang B, Cheng Z, Chen J, ɛn ɔda pipul dɛn. Efficacy ɛn Sefty fɔ Mazdutide in Chaynish Patient dɛn wit Tayp 2 Dayabitis: Wan Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial[J]. Dayabitis Keya, 2024,47(1):160-168.DOI:10.2337/dc23-1287.

[2] Ji L, Jiang H, Cheng Z, ɛn ɔda pipul dɛn. A phase 2 randomized controlled trial of mazdutide in Chaynish ɔvaweit big pipul ɔ big pipul dɛn we gɛt fat[J]. Nature Komyunikeshɔn, 2023,14(1).DOI: 10.1038/s41467-023-44067-4.

[3] Nalisa D. L., Kuboia N, Dyab E, ɛn ɔda pipul dɛn. Efikεsi εn sef fכ Mazdutide pan wεyt lכs bitwin dayabεtik εn nכn-dayabεtik pasεnshכn dεm: wan sεstεmatik rivyu εn mεta-analysis כf randomizεd kכntrold trayal dεm[J]. Frontiers in Ɛndokrinɔlɔji, 2024,15.

[4] Morris A. Unraveling nכvel weit lכs mεkanism dεm[J]. Nature Rivyu Ɛndokrinɔlɔji, 2020,16(7):343.DOI:10.1038/s41574-020-0374-4.

[5] Ji L, Gao L, Jiang H, ɛn ɔda pipul dɛn. Sefty ɛn ɛfifikɛshɔn fɔ wan GLP-1 ɛn glukagɔn riseptɔ dual agonist mazdutide (IBI362) 9 mg ɛn 10 mg insay Chaynish big pipul dɛn we gɛt ɔvawej ɔ fat: Wan randomiz, plasɛbo-kɔntrol, mɔltipɛl-asɛnd-dɔz faz 1b trayal[J]. Eklinikalmɛdisin, 2022,54:101691.DOI:10.1016/j.ɛklinm.2022.101691.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL DI INFƆMƐSHƆN DISƐMƐNƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.